Get all premium features to the best stock analysis tool

A Ligand insider sold 3,057 shares of common stock on March 11, 2026, for $688,000. The transaction represented 12.70% of his direct common stock holdings, reducing his position from 24,067 to 21,010 shares.

JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development.

Arecor Therapeutics PLC (AIM:AREC), the Cambridge-based biotech focused on diabetes and cardiometabolic treatments, has received a $500,000 commercial milestone payment from Ligand Pharmaceuticals under a royalty financing agreement struck in September 2025. The payment is the first milestone tranche under a deal in which Arecor sold Ligand the global royalty rights to AT220, an enhanced biosimilar insulin product, and related rights to AT292, a therapy licensed to Sanofi, in exchange for an initial $7 million upfront and up to $4 million in milestone payments.

Shares of Ligand Pharmaceuticals dropped into a sell zone Thursday, seemingly down in sympathy with the broader biotech segment.

Bank of America (BofA) Securities on Wednesday initiated coverage on Ligand Pharmaceuticals Inc (NASDAQ: LGND), citing the distinctive royalty firm offers compelling upside.

Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company's royalty-focused business model and diversified portfolio as key drivers of continued earnings growth. Ligand provides capital and technology to drug and medical device developers in exchange for royalties, creating a portfolio of more than 100 commercial and development-stage assets that generate high-margin returns.

Solid pharma stocks offer promising upside opportunities. This particular play is eyeing an entry as earnings surge.